A Novel Transdiagnostic Approach to the Prevention of Eating Disorders Using Virtual Reality: Preliminary Evaluation of the H.O.M.E. Intervention
Abstract
"Virtual reality" (VR) has been used effectively in clinical psychology to improve existing treatments and prevention protocols for many psychopathologies, including eating disorders (EDs). However, no VR software was developed to concurrently tackle dysfunctional eating behaviours and three third wave cognitive-behavioural transdiagnostic factors linked to EDs: psychological inflexibility, emotion dysregulation and experiential avoidance. This preliminary study is aimed at evaluating potential effects of a new VR-based preventive intervention (H.O.M.E.-How to Observe and Modify Emotions) in improving selected outcomes of transdiagnostic factors and dysfunctional eating behaviours in the general population (GP) with ED risk compared to a waiting list (WL). N = 40 GP participants with ED risk were screened (using the SCOFF and Eating Disorder Examination Questionnaire (EDE-Q)) and randomised into VR (n = 20) or WL (n = 20) groups. Before and after intervention and at 3- and 6-month follow-up, participants completed EDE-Q, Difficulties in Emotion Regulation Scale-brief version (DERS-16) for emotion dysregulation, Acceptance and Action Questionnaire II (AAQ-II) for psychological inflexibility and Multidimensional Psychological Flexibility Inventory (MPFI) experiential avoidance scale. H.O.M.E. improved scores in all EDE-Q subscales (EDE-Q-total: p = 0.003; EDE-Q-restraint: p = 0.028; EDE-Q-eating concerns: p = 0.035; EDE-Q-shape concerns: p = 0.003; EDE-Q-weight concerns: p =…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 40 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.